×
Choose Speciality

EXPLORE!

LOGIN

FDA recommends against using Exparel as regional nerve block

  1286 Views

eMediNexus    25 February 2018

The US Food and Drug Administrations (FDAs) Anesthetic and Analgesic Drug Products Advisory Committee has voted 6 to 4 against recommending bupivacaine liposomal injectable suspension (Exparel, Pacira Pharmaceuticals Inc) as a nerve block to treat regional postsurgical pain.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.